Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-Arm Phase 1 Trial [72]. This evidence concerns the gene FOLH1 and prostate carcinoma.